Business Wire08.04.17
ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that a federal jury in Boston awarded it $3.3 million in damages for patent infringement by Philips Electronics North America Corporation. ZOLL’s two patents were associated with high-impedance defibrillation electrodes that reduce burns, and monitoring for life-threatening heart rhythms.
The jury also determined that ZOLL should pay Philips and its parent company $8.9 million in damages for infringement of one patent concerning performing wake-up self-tests in an AED, plus $1.5 million for infringing two patents associated with monitoring patient impedance while delivering a biphasic waveform. Philips had been seeking total damages of $217 million, the vast majority for infringement of the two waveform patents.
“We are satisfied that the jury has been fair in awarding reasonable damages under the circumstances,” said Jonathan Rennert, CEO. “The patents in question are all expired and there is no impact on ZOLL’s day-to-day business. We look forward to continuing to focus on market opportunities where our defibrillator technology enjoys standard of care status.”
Both companies had previously been found liable for infringing each other’s defibrillator-related patents in a separate jury trial in 2013.
The jury also determined that ZOLL should pay Philips and its parent company $8.9 million in damages for infringement of one patent concerning performing wake-up self-tests in an AED, plus $1.5 million for infringing two patents associated with monitoring patient impedance while delivering a biphasic waveform. Philips had been seeking total damages of $217 million, the vast majority for infringement of the two waveform patents.
“We are satisfied that the jury has been fair in awarding reasonable damages under the circumstances,” said Jonathan Rennert, CEO. “The patents in question are all expired and there is no impact on ZOLL’s day-to-day business. We look forward to continuing to focus on market opportunities where our defibrillator technology enjoys standard of care status.”
Both companies had previously been found liable for infringing each other’s defibrillator-related patents in a separate jury trial in 2013.